Biofil Chemicals & Pharmaceuticals Ltd
Pharmaceuticals | Small Cap
Biofil Chemicals & Pharmaceuticals Ltd operates within the Pharmaceuticals & Biotechnology sector. The company exhibits strengths in solvency and growth, driven by low debt levels and robust revenue and asset expansion. However, profitability metrics, such as gross profit margin, return on capital employed, return on equity and return on assets needs improvement. Efficiency ratios also indicate potential challenges in managing inventory and receivables. While the company's coverage ratios are strong, financial ratios suggest concerns with earnings per share and book value. The company demonstrates good revenue growth and management of its assets, but struggles in converting sales into profit and also needs to enhance profitability and efficiency to ensure sustainable financial health.
Latest Report
View AllThe Latest Reports Are Not Available at the Moment. We’ll Notify You Once They’re Available.
Latest News
View AllThe Latest News Is Not Available at the Moment. We’ll Notify You Once It’s Available.
- Valuation MetricsNeutral
- Market Metrics
- Stock Reports
- Stock News
- Growth Ratio5.30
- Financial Ratio4.00
- Profitability Ratio2.00
- Efficiency Ratio2.00
- Coverage Ratio10.00
- Solvency Ratio10.00
- Liquidity Ratio0.00
- Peer Assessment
- Management AssessmentBalanced
- Risk AssessmentBalanced
- 1 HourBullish
- 2 HoursStrong Bullish
- 4 HoursBullish
- 1 DayBullish
- 1 WeekBullish
- 1 MonthNeutral
Biofil Chemicals & Pharmaceuticals Ltd operates within the Pharmaceuticals & Biotechnology sector. The company exhibits strengths in solvency and growth, driven by low debt levels and robust revenue and asset expansion. However, profitability metrics, such as gross profit margin, return on capital employed, return on equity and return on assets needs improvement. Efficiency ratios also indicate potential challenges in managing inventory and receivables. While the company's coverage ratios are strong, financial ratios suggest concerns with earnings per share and book value. The company demonstrates good revenue growth and management of its assets, but struggles in converting sales into profit and also needs to enhance profitability and efficiency to ensure sustainable financial health.
Overall Valuation Score
P/E RATIO (TTM)
19.61
Industry Median
19.41
Small Cap Median
18.08
P/E RATIO
100.94
P/B RATIO
2.62
Industry Median
1.98
Small Cap Median
2.03
P/S RATIO
N/A
Industry Median
2.06
Small Cap Median
1.64
Others
PEG RATIO
-7.06
EV/EBITDA RATIO
48.23
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹34.32 as on Feb 20, 2026.
Unlock Live Chart
Please login to view interactive real-time technical charts powered by TradingView.
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
0.00
Today's Low
0.00
Today's High
The company has mixed performance in growth metrics. Strong revenue and asset growth rates indicate good expansion. However, declines in operating profit and EPS growth suggest that profitability is not keeping pace with revenue. This could be due to rising costs or reduced efficiency. While the company is expanding, it needs to focus on improving profitability to ensure sustainable growth. However, high asset growth might be due to strategic investments in R&D or infrastructure, which could yield long-term benefits.
| Growth Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Revenue Growth Rate | N/A | N/A | N/A | N/A | N/A |
| Operating Profit Growth Rate | -12.09 | -16.88 | -12.78 | -30.17 | 4.94 |
| Earnings Per Share (EPS) Growth | 2.7 | -43.42 | -20.93 | 29.41 | -22.73 |
| Asset Growth Rate | N/A | -43.65 | 67.65 | 49.94 | 8.22 |
| Net Income Growth Rate | N/A | N/A | N/A | N/A | N/A |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
The company's financial ratios present a mixed picture. While capital expenditures are well-managed, earnings per share and book value per share are not strong. This suggests potential issues with profitability and shareholder value. The company needs to address these weaknesses to improve overall financial performance and investor confidence. A higher capital expenditure may indicate investment in future growth prospects.
| Financial Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Adjusted Earnings Per Share (Adjusted EPS) | N/A | N/A | N/A | N/A | N/A |
| Cash Earnings Per Share (Cash EPS) | N/A | N/A | N/A | N/A | N/A |
| Book Value Per Share | 9.9 | 10.33 | 10.61 | 11.17 | 11.52 |
| Dividend Per Share (DPS) | 0 | 0 | 0 | 0 | 0 |
| Capital Expenditures (CapEx) | 0 | 0 | 0 | 0 | 0 |
Adjusted Earnings Per Share (Adjusted EPS)
Cash Earnings Per Share (Cash EPS)
Book Value Per Share
Dividend Per Share (DPS)
Capital Expenditures (CapEx)
The company's profitability ratios are generally weak, indicating challenges in generating profits from sales and assets. Low gross profit margin, ROCE, ROE, and ROA suggest issues with cost management and operational efficiency. This can impact investor confidence and long-term sustainability. The company needs to focus on improving its profitability metrics to enhance its financial health. However, lower profitability in the short term might be due to strategic investments in R&D or marketing, which could yield higher returns in the future.
| Profitability Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Gross Profit Margin | N/A | N/A | N/A | N/A | N/A |
| Return on Capital Employed (ROCE) | N/A | N/A | N/A | N/A | N/A |
| Return on Equity (ROE) | N/A | N/A | N/A | N/A | N/A |
| Return on Assets (ROA) | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
Gross Profit Margin
Return on Capital Employed (ROCE)
Return on Equity (ROE)
Return on Assets (ROA)
Operating Margin
Net Margin
The company's efficiency ratios suggest potential issues in managing inventory and receivables. Extended receivable days and inventory turnover rates may indicate difficulties in converting sales into cash. This can impact cash flow and working capital management. The company needs to focus on optimizing its operations to improve overall efficiency and financial performance. However, a lower efficiency score can reflect a strategy of holding larger inventory to meet demand or offering more flexible credit terms to boost sales.
| Efficiency Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Fixed Asset Turnover Ratio | N/A | N/A | N/A | N/A | N/A |
| Inventory Turnover Ratio | N/A | N/A | N/A | N/A | N/A |
| Receivables Turnover Ratio | N/A | N/A | N/A | N/A | N/A |
| Days Sales in Inventory Ratio | N/A | N/A | N/A | N/A | N/A |
| Receivable Days | N/A | N/A | N/A | N/A | N/A |
| Capital Turnover Ratio | 0 | 0 | 0 | 0 | 0 |
Inventory Turnover Ratio
Receivables Turnover Ratio
Days Sales in Inventory Ratio
Receivable Days
The company has a strong coverage ratio, indicating it can comfortably meet its interest obligations. This suggests financial stability and a low risk of financial distress. This also provides a cushion against economic downturns or unexpected expenses. Potential investors may view the high-interest coverage as a sign of financial prudence. However, the company needs to balance this with the potential benefits of leveraging debt for growth.
| Coverage Ratios | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Interest Coverage Ratio | 13.17 | 28.43 | 26.25 | 20.75 | 22.5 | 19.5 |
| Equity Dividend Coverage Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
Interest Coverage Ratio
The company maintains a strong position in terms of solvency. Low debt and high-interest coverage suggest it can comfortably meet its financial obligations. This indicates financial stability and reduces the risk of financial distress. Potential investors may view the low debt levels as a sign of financial prudence. However, relying heavily on equity financing might limit the company's ability to leverage opportunities for growth.
| Solvency Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 | 0 | 0 |
| Debt to Equity Ratio | 0 | 0 | 0 | 0 | 0 |
| Equity Ratio | 1 | 1 | 1 | 1 | 1 |
| Debt To Asset Ratio | 0 | 0 | 0 | 0 | 0 |
Debt Ratio
Debt to Equity Ratio
Interest Coverage Ratio
The liquidity position cannot be determined due to unavailability of data.
| Liquidity Ratios | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|
| Current Ratio | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A |
| Cash Ratio | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow Ratio | N/A | N/A | N/A | N/A | N/A |
Current Ratio
Quick Ratio
Cash Ratio
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Biofil Chemicals & Pharmaceuticals Ltd | 4.22 | 100.94 | Neutral | 0.85 | 0.34 | 0.56 |
The management of Biofil Chemicals & Pharmaceuticals Ltd presents a mixed performance. Consistent promoter holding indicates stable ownership. However, fluctuating sales growth, declining profit margins, and low capital efficiency raise concerns. Debt management is stable, but overall financial health suggests caution.
| Category | Metric | Value | Assessment |
|---|---|---|---|
| PROS | Consistent Promoter Holding | 46.82% | Stable ownership structure |
| CONS | Declining OPM | 2.02% (Mar 2024) | Indicates weakening operational efficiency |
| Fluctuating Sales Growth | -86% (Sep 2024) | Inconsistent revenue expansion | |
| Low ROCE | 4.94% | Poor capital utilization |
Financial Performance & Growth
Biofil Chemicals & Pharmaceuticals demonstrates inconsistent financial performance. Sales growth varies significantly, and OPM has declined, reflecting weakening operational efficiency. Net profit margins also display volatility, affecting overall profitability.
| Metric | Sep 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| YOY Sales Growth % | -14% | -49% | -88% | 129% | -81% | -9% | 725% | -80% | 563% | 238% | 12% | 247% | -86% |
| OPM % | 2.69% | 29.45% | 8.48% | 3.01% | 6.11% | 15.44% | 3.01% | 17.28% | 1.38% | 3.78% | -0.26% | 3.67% | 4.98% |
Capital Efficiency & Returns
The capital efficiency of Biofil Chemicals & Pharmaceuticals is relatively poor. ROCE is low, indicating inefficient capital utilization. ROE is also low, suggesting that shareholder funds are not yielding substantial returns.
| Metric | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 8.83% | 7.66% | 8.59% | 9.64% | 18.72% | 5.06% | 5.00% | 10.08% | 12.20% | 6.20% | 4.73% | 4.94% |
Financial Health & Prudence
Biofil Chemicals & Pharmaceuticals exhibits average financial health. The company's debt management appears to be under control, with stable borrowings. However, the company does not distribute dividends, which may impact investor perception.
| Metric | 2013-2015 | 2016-2018 | 2019-2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Average Borrowings | 2.85 | 1.45 | 0.69 | 0.46 | 0.52 | 0.44 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Strategic & Operational Indicators
Strategic and operational indicators for Biofil Chemicals & Pharmaceuticals show mixed efficiency. Debtor days are high, indicating challenges in collecting receivables efficiently. Inventory days are relatively low. The cash conversion cycle varies, reflecting fluctuations in working capital management.
| Metric | 2013-2015 | 2016-2018 | 2019-2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Debtor Days (Average) | 212.97 | 350.59 | 243.00 | 116.94 | 249.08 | 301.10 |
The risk assessment for Biofil Chemicals & Pharmaceuticals is rated as Orange due to fluctuating sales growth and declining profit margins. High debtor days and a volatile cash conversion cycle pose operational risks. The company's financial health is average, with manageable debt but inconsistent profitability.
Off-balance sheet exposure quantification
There is no specific data available to quantify off-balance sheet exposures for Biofil Chemicals & Pharmaceuticals. Without this information, it is difficult to assess potential financial risks and obligations that are not reflected on the balance sheet.
Contingent liability evaluation
There is no specific data available regarding contingent liabilities of Biofil Chemicals & Pharmaceuticals. Contingent liabilities represent potential obligations depending on future events. The absence of this information makes it difficult to evaluate potential financial risks associated with unforeseen liabilities.
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1035.58Bullish
- SMA 2035.66Bullish
- SMA 5035.77Bullish
- EMA 1035.71Bullish
- EMA 2035.66Bullish
- EMA 5035.68Bullish
- DEMA 1035.84Bullish
- DEMA 2035.65Bullish
- DEMA 5035.77Bullish
- TEMA 1035.98Bullish
- TEMA 2035.74Bullish
- TEMA 5035.54Bullish
- MACD0.01Bullish
- ADX34.73Strong Trend
- IndicatorValueSignal
- RSI60.04Neutral
- CCI122.73Overbought
- ROC 91.99Bullish
- ROC 141.42Bullish
- ROC 251.90Bullish
- Stoch K80.57Overbought
- Stoch D69.59Neutral
- IndicatorValueSignal
- BB Upper36.34Overbought
- BB Middle35.66Neutral
- BB Lower34.98Neutral
- ATR0.60High Volatility
- IndicatorValueSignal
- MFI69.64Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 2 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1035.66Bullish
- SMA 2035.68Bullish
- SMA 5035.70Bullish
- EMA 1035.68Bullish
- EMA 2035.69Bullish
- EMA 5035.51Bullish
- DEMA 1035.72Bullish
- DEMA 2035.67Bullish
- DEMA 5036.03Bullish
- TEMA 1035.83Bullish
- TEMA 2035.59Bullish
- TEMA 5035.88Bullish
- MACD-0.01Bullish
- ADX37.61Strong Trend
- IndicatorValueSignal
- RSI58.56Neutral
- CCI80.90Neutral
- ROC 90.83Bullish
- ROC 142.16Bullish
- ROC 251.25Bullish
- Stoch K44.72Neutral
- Stoch D31.03Neutral
- IndicatorValueSignal
- BB Upper36.43Neutral
- BB Middle35.68Neutral
- BB Lower34.94Neutral
- ATR0.90Low Volatility
- IndicatorValueSignal
- MFI76.58Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 4 Hours Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bearish
- IndicatorValueSignal
- SMA 1035.75Bullish
- SMA 2035.89Bullish
- SMA 5034.60Bullish
- EMA 1035.78Bullish
- EMA 2035.65Bullish
- EMA 5034.91Bullish
- DEMA 1035.82Bullish
- DEMA 2036.03Bullish
- DEMA 5036.07Bullish
- TEMA 1035.78Bullish
- TEMA 2035.85Bullish
- TEMA 50N/AN/A
- MACD0.25Bearish
- ADX37.47Strong Trend
- IndicatorValueSignal
- RSI56.46Neutral
- CCI11.03Neutral
- ROC 90.55Bullish
- ROC 141.62Bullish
- ROC 257.98Bullish
- Stoch K23.89Neutral
- Stoch D18.95Oversold
- IndicatorValueSignal
- BB Upper36.97Neutral
- BB Middle35.89Neutral
- BB Lower34.81Neutral
- ATR1.49Low Volatility
- IndicatorValueSignal
- MFI86.10Overbought
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 33 Technical Indicators From The 1 Day Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 1035.77Bullish
- SMA 2035.13Bullish
- SMA 5034.11Bullish
- SMA 10033.20Bullish
- SMA 20035.74Bullish
- EMA 1035.57Bullish
- EMA 2035.09Bullish
- EMA 5034.13Bullish
- EMA 10034.14Bullish
- EMA 20036.56Bearish
- DEMA 1035.96Bullish
- DEMA 2035.98Bullish
- DEMA 5034.97Bullish
- DEMA 10032.82Bullish
- DEMA 20030.69Bullish
- TEMA 1035.83Bullish
- TEMA 2036.13Bearish
- TEMA 5036.05Bearish
- TEMA 10034.65Bullish
- TEMA 20031.23Bullish
- MACD0.66Bearish
- ADX41.45Strong Trend
- IndicatorValueSignal
- RSI57.93Neutral
- CCI25.69Neutral
- ROC 143.53Bullish
- ROC 2510.92Bullish
- Stoch K44.43Neutral
- Stoch D41.49Neutral
- IndicatorValueSignal
- BB Upper37.78Neutral
- BB Middle35.13Neutral
- BB Lower32.47Neutral
- ATR2.22Low Volatility
- IndicatorValueSignal
- MFI34.85Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 21 Technical Indicators From The 1 Week Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 2032.96Bullish
- SMA 5037.09Bearish
- EMA 2033.81Bullish
- EMA 5037.48Bearish
- DEMA 2032.77Bullish
- DEMA 5030.48Bullish
- TEMA 2034.51Bullish
- TEMA 5029.93Bullish
- MACD-0.51Bullish
- ADX18.62Weak Trend
- IndicatorValueSignal
- RSI50.10Neutral
- CCI-9.81Neutral
- ROC 1417.50Bullish
- ROC 2510.42Bullish
- Stoch K69.10Neutral
- Stoch D63.62Neutral
- IndicatorValueSignal
- BB Upper38.04Neutral
- BB Middle32.96Neutral
- BB Lower27.88Neutral
- ATR4.17High Volatility
- IndicatorValueSignal
- MFI73.71Neutral
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 25 Technical Indicators From The 1 Month Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
- IndicatorValueSignal
- SMA 631.63Bullish
- SMA 1237.08Bearish
- SMA 2447.79Bearish
- EMA 633.60Bullish
- EMA 1237.14Bearish
- EMA 2443.11Bearish
- DEMA 631.52Bullish
- DEMA 1230.20Bullish
- DEMA 2434.88Bullish
- TEMA 633.17Bullish
- TEMA 1229.42Bullish
- TEMA 2429.27Bullish
- MACD-4.22Bearish
- ADX16.08Weak Trend
- IndicatorValueSignal
- RSI45.83Neutral
- CCI-116.62Oversold
- ROC 25-50.16Bearish
- ROC 50-39.13Bearish
- Stoch K7.07Oversold
- Stoch D21.85Neutral
- IndicatorValueSignal
- BB Upper65.36Neutral
- BB Middle43.45Neutral
- BB Lower21.54Neutral
- ATR10.75Low Volatility
- IndicatorValueSignal
- MFI76.34Neutral